MD — Pediatrix Medical Balance Sheet
0.000.00%
- $1.70bn
- $1.80bn
- $1.91bn
Annual balance sheet for Pediatrix Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 487 | 103 | 178 | 349 | 500 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 316 | 297 | 280 | 273 | 242 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 841 | 428 | 483 | 640 | 764 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 136 | 140 | 146 | 78.4 | 73.5 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,723 | 2,348 | 2,220 | 2,153 | 2,247 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 427 | 427 | 389 | 434 | 459 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1,826 | 1,456 | 1,371 | 1,388 | 1,381 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 896 | 892 | 849 | 765 | 866 |
| Total Liabilities & Shareholders' Equity | 2,723 | 2,348 | 2,220 | 2,153 | 2,247 |
| Total Common Shares Outstanding |